Skip to main content
. 2024 Feb 16;30(2):435–442. doi: 10.1038/s41591-023-02794-7

Fig. 1. Study design.

Fig. 1

Overview of the study design. Participants with kidney failure undergoing hemodialysis were randomized to receive lower- or higher-dose osocimab or placebo for ≤18 months. The follow-up period ended 5 months after the last study intervention and 4 months after the end of the main or extension treatment period.